^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    CHPF (Chondroitin Polymerizing Factor)

    i
    Other names: CHPF, Chondroitin Polymerizing Factor, CSS2, Chondroitin Sulfate Synthase 2, CHSY2, Glucuronosyl-N-Acetylgalactosaminyl-Proteoglycan 4-Beta-N-Acetylgalactosaminyltransferase II, N-Acetylgalactosaminyl-Proteoglycan 3-Beta-Glucuronosyltransferase II, N-Acetylgalactosaminyltransferase 2, Chondroitin Glucuronyltransferase 2, Chondroitin-Polymerizing Factor, ChPF
    Associations

    News

    Trials
    over1year
    Analysis of the role of CHPF in colorectal cancer tumorigenesis and immunotherapy based on bioinformatics and experiments. (PubMed, Discov Oncol)
    CHPF could promote the proliferation and migration of CRC cells and lead to poor prognosis, possibly through wnt pathways as well as changes in TME. Patients with high expression of CHPF had poor efficacy in immunotherapy, which might be related to Tregs cell infiltration. Above all, it might offer more reliable guidance for future immunotherapy.
    Journal • Tumor mutational burden • MSi-H Biomarker • PD(L)-1 Biomarker • IO biomarker
    |
    TMB (Tumor Mutational Burden) • MSI (Microsatellite instability) • PD-1 (Programmed cell death 1) • CHPF (Chondroitin Polymerizing Factor)
    |
    MSI-H/dMMR
    |
    Mekinist (trametinib) • serdemetan (JNJ-26854165) • telatinib (BAY 57- 9352)
    over1year
    Identification of a Novel Five-Gene Prognostic Model for Laryngeal Cancer Associated with Mitophagy Using Integrated Bioinformatics Analysis and Experimental Verification. (PubMed, Crit Rev Immunol)
    RT-qPCR showed that CERCAM, CHPF, EXT2, and MED15 expression were upregulated, and EPHX3 level was decreased in LC cells. The present study established a five-mitophagy-related-gene model that can predict the prognosis of LC patients, thus laying the foundation for a better understanding and potential advancements in clinical treatments for LC.
    Journal
    |
    CHPF (Chondroitin Polymerizing Factor)
    over1year
    Genotyping of unresectable soft tissue sarcomas (EACR 2024)
    Many sarcomas may be driven by gene fusions. However, further research is needed on a larger group of patients.
    TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1) • ATM (ATM serine/threonine kinase) • PDGFRA (Platelet Derived Growth Factor Receptor Alpha) • NF1 (Neurofibromin 1) • JAK2 (Janus kinase 2) • PIK3CD (Phosphatidylinositol-4 5-Bisphosphate 3-Kinase Catalytic Subunit Delta) • EP300 (E1A binding protein p300) • AKT3 (V-akt murine thymoma viral oncogene homolog 3) • BCL2L2 (BCL2 Like 2) • MAP3K1 (Mitogen-Activated Protein Kinase Kinase Kinase 1) • DICER1 (Dicer 1 Ribonuclease III) • CHPF (Chondroitin Polymerizing Factor) • SLC25A3 (Solute Carrier Family 25 Member 3) • TRPC6 (Transient Receptor Potential Cation Channel Subfamily C Member 6)
    |
    TruSight Oncology 500 Assay
    almost2years
    Chondroitin polymerizing factor promotes development and progression of colorectal cancer via facilitating transcription of VEGFB. (PubMed, J Cell Mol Med)
    Functionally, suppressing VEGFB expression successfully mitigated the oncogenic effects induced by CHPF overexpression. Collectively, these findings suggest that CHPF may act as a tumour promoter in CRC, operating in a VEGFB-dependent manner and could be a potential target for therapeutic interventions in CRC treatment.
    Journal
    |
    VEGFB (Vascular Endothelial Growth Factor B) • CHPF (Chondroitin Polymerizing Factor) • E2F1 (E2F transcription factor 1)
    |
    VEGFB expression
    almost2years
    Targeting chondroitin sulfate suppresses macropinocytosis of breast cancer cells by modulating syndecan-1 expression. (PubMed, Mol Oncol)
    Furthermore, C6S-p demonstrated the ability to bind CS-SDC1, increase SDC1 degradation, suppress macropinocytosis of breast cancer cells, and inhibit tumor growth in vivo. Although other PGs may also be involved in CHPF-regulated breast cancer malignancy, this study provides the first evidence that a CS synthase participates in the regulation of macropinocytosis in cancer cells by supporting SDC1 expression on cancer cells.
    Journal
    |
    SDC1 (Syndecan 1) • TGFB1 (Transforming Growth Factor Beta 1) • CHPF (Chondroitin Polymerizing Factor)
    |
    SDC1 expression
    almost2years
    Chondroitin polymerizing factor (CHPF) promotes the progression of colorectal cancer through ASB2-mediated ubiquitylation of SMAD9. (PubMed, Histol Histopathol)
    Mechanistically, SMAD9 is ubiquitinated by ASB2, and the regulatory effect of CHPF on SMAD9 activity was exerted via its mediation of ASB2. Collectively, CHPF functioned as a promising prognostic biomarker and tumor-promoter of CRC by regulating the ASB2-mediated ubiquitination of SMAD9.
    Journal
    |
    CHPF (Chondroitin Polymerizing Factor) • SMAD9 (SMAD Family Member 9)
    2years
    Activation of CHPF by transcription factor NFIC promotes NLRP3 activation during the progression of colorectal cancer. (PubMed, Funct Integr Genomics)
    Additionally, nuclear factor 1 C-type (NFIC) was revealed as a potential upstream transcription factor of CHPF in the modulation of CRC, and the anti-tumor effects elicited through its knockdown were compromised by CHPF in vitro and in vivo. In summary, we demonstrated that NFIC promoted NLRP3 activation to support CRC development via the CHPF-mediated MAPK signaling.
    Journal
    |
    MAP2K1 (Mitogen-activated protein kinase kinase 1) • MAP2K2 (Mitogen-activated protein kinase kinase 2) • NLRP3 (NLR Family Pyrin Domain Containing 3) • CHPF (Chondroitin Polymerizing Factor) • NFIC (Nuclear Factor I C)
    2years
    MEK-mediated CHPF2 phosphorylation promotes colorectal cancer cell proliferation and metastasis by activating NF-κB signaling. (PubMed, Cancer Lett)
    These findings identify a moonlighting function of CHPF2 in promoting tumor cell proliferation and metastasis and provide insights into the mechanism by which CHPF2 amplifies TNF-mediated NF-κB signaling activation. Our study provides a molecular basic for the development of therapeutic strategies for CRC treatment.
    Journal
    |
    TNFA (Tumor Necrosis Factor-Alpha) • CHPF (Chondroitin Polymerizing Factor) • EGR1 (Early Growth Response 1) • RELA (RELA Proto-Oncogene)
    2years
    MiR-214-3p overexpression-triggered chondroitin polymerizing factor (CHPF) inhibition modulates the ferroptosis and metabolism in colon cancer. (PubMed, Kaohsiung J Med Sci)
    Upregulation of miR-214-3p reduced cell viability, glucose uptake, lactate product, and ATP level, but increased the levels of ferrous iron and ROS, which were reversed by the overexpression of CHPF. Upregulation of CHPF predicted poor prognosis, and miR-214-3p/CHPF axis inhibited growth, downregulated the levels of glycolysis-related indexes, and promoted ferroptosis in colon cancer cells.
    Journal
    |
    CHPF (Chondroitin Polymerizing Factor) • MIR214 (MicroRNA 214)
    over2years
    The HNF4A-CHPF pathway promotes proliferation and invasion through interactions with MAD1L1 in glioma. (PubMed, Aging (Albany NY))
    Immunoprecipitation, co-immunoprecipitation, GST pulldown, and liquid chromatography-mass spectrometry (LC-MS/MS) assays were used to verify the interaction between CHPF and Mitotic arrest deficient 1-like 1 (MAD1L1). In addition, Chromatin Immunoprecipitation (ChIP)-PCR analysis showed that HNF4A bound to the CHPF promoter region, which indicated that the transcription factor hepatocyte nuclear factor 4A (HNF4A) could regulate the expression of CHPF in glioma cells.
    Journal
    |
    MAD1L1 (Mitotic Arrest Deficient 1 Like 1) • CHPF (Chondroitin Polymerizing Factor) • HNF1A (HNF1 Homeobox A)
    over2years
    Chondroitin Polymerizing Factor (CHPF) promotes cell proliferation and tumor growth in human osteosarcoma by inhibiting SKP2's ubiquitination while activating the AKT pathway. (PubMed, Genes Dis)
    Exploration of the mechanism by which CHPF promotes osteosarcoma indicated that CHPF promotes osteosarcoma through counteracting SKP2's ubiquitination and activating the Akt signaling pathway. For the first time, we clarified the roles of CHPF in osteosarcoma, and our results suggested that CHPF might be a novel therapeutic target in the treatment strategies for osteosarcoma.
    Journal
    |
    CHPF (Chondroitin Polymerizing Factor) • SKP2 (S-phase kinase-associated protein 2)
    over2years
    Exploring the correlation of glycolysis-related chondroitin polymerizing factor (CHPF) with clinical characteristics, immune infiltration, and cuproptosis in bladder cancer. (PubMed, Am J Cancer Res)
    The CHPF expression levels were also positively associated with F-fluorodeoxyglucose uptake in PET/CT images. We conclude that the glycolysis-related gene CHPF is an effective diagnostic and treatment target for BLCA.
    Journal • IO biomarker
    |
    CHPF (Chondroitin Polymerizing Factor)